LOW-GRADE INFLAMMATION IN SUBCLINICAL HYPOTHYROIDISM: ROLE OF HIGHSENSITIVE C-REACTIVE PROTEIN by Kumar, Pradeep et al.
Vol 11, Issue 9, 2018
Online - 2455-3891 
Print - 0974-2441
LOW-GRADE INFLAMMATION IN SUBCLINICAL HYPOTHYROIDISM: ROLE OF HIGH-
SENSITIVE C-REACTIVE PROTEIN
PRADEEP KUMAR1, PREETI SHARMA1*, RACHNA SHARMA2, GAURAV GUPTA3, ANCHAL CHAUDHARY1
1Department of Biochemistry, Santosh Medical College and Hospital, Ghaziabad, Uttar Pradesh, India. 2Department of Biochemistry, TSM 
Medical College and Hospital, Lucknow, Uttar Pradesh, India. 3Department of Biochemistry, Govt. Medical College and Hospital, Badaun, 
Uttar Pradesh, India. Email: prcdri2003@yahoo.co.in
Received: 20 April 2018, Revised and Accepted: 01 June 2018
ABSTRACT
Objective: Subclinical hypothyroidism (SCH) patients may present with abnormal lipid profile more specifically in patients having thyroid-stimulating 
hormone (TSH) >10 mIU/L. Since the contradiction still lies with patients having TSH <10 mIU/L, so the role of high-sensitive C-reactive protein (Hs-
CRP) may be important with the prediction of inflammatory cardiovascular risk.
Methods: Recently diagnosed 30 SCH patients both male and female were recruited and compared 30 normal healthy adults. Age and body mass 
index (BMI) of the study population were noted. Thyroid profile including TSH, FT4, and T3 was measured by an enzyme-linked immunosorbent assay 
(ELISA). Total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol were measured by the CHOD-POD method, GPO-PAP method, 
and CHOD-POD/phosphotungstic method. Low-density lipoprotein (LDL) cholesterol and very low-density cholesterol were measured by Friedewald 
formula. Lipoprotein ratios were also calculated. An ELISA was also used for the estimation of Hs-CRP.
Results: The significant results were obtained in this study. BMI was significantly (<0.01) elevated in patients’ group compared to the control group. In 
the thyroid profile, TSH was significantly (<0.05) different between the groups. Total cholesterol, triglycerides, and LDL-cholesterol were significantly 
(<0.01) elevated in the case group. A significantly lower concentration of HDL cholesterol was observed in SCH patients when compared with control 
subjects. There was an elevated concentration of lipoprotein ratios in patients group. The mean concentration of Hs-CRP was highly significant 
between the groups. The level was higher in the case group compared to the control group. In patients’ group, there was a positive association (β-
0.36) (confidence interval 95%–0.002–0.536) between TSH and Hs-CRP. This association was highly significant.
Conclusion: SCH patients having TSH <10 μIU/ml were characterized by dyslipidemia and elevated Hs-CRP. Increased lipoprotein ratios and Hs-CRP 
may promote low-grade inflammation in SCH patients, by which cardiovascular risk can be developed.
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INTRODUCTION
Subclinical hypothyroidism (SCH) is the most common endocrine 
disease worldwide. SCH is characterized by an elevated 
concentration of thyroid-stimulating hormone (TSH) above the 
reference range and normal concentration of free thyroxine (FT4) 
and triiodothyronine (T3) [1]. SCH is a biochemical disorder 
rather than clinical disorder since patients with SCH are generally 
asymptomatic or present with non-specific symptoms of overt 
hypothyroidism. Hence, the patients are diagnosed with SCH on 
the basis of thyroid profile picture [2]. Studies in the past have 
evaluated that the presence of dyslipidemia may not be neglected in 
patients, more specifically in moderate SCH having TSH >10 mIU/L, 
but the results were contradictory [3,4]. Since the presence of 
dyslipidemia may suggest future progression of cardiovascular 
risks, the role of inflammatory markers may be important in 
SCH patients because without inflammation cholesterol cannot 
be trapped [5,6]. High-sensitive C-reactive protein (Hs-CRP), a 
diagnostic tool for assessment of cardiovascular disease, is a marker 
of low-grade inflammation, which may lead to atherosclerosis [7]. 
Estimation of Hs-CRP may be valuable since it is an effective marker 
for heart diseases rather than low-density lipoprotein (LDL) 
cholesterol alone [8]. Hs-CRP may evaluate the status of low-grade 
inflammation in patients with SCH. Therefore, the main objective of 
this study was to an assessment of Hs-CRP in SCH patients having 
TSH <10 mIU/l along with lipid profile.
METHODS
This cross-sectional study was carried out in the Department of 
Biochemistry, Santosh Medical College and Hospital, Ghaziabad. All the 
participants voluntarily participated in this study. Written consent was 
obtained from each individual. This study was ethically approved by 
the institutional ethical committee. 30 recently diagnosed SCH patients 
were enrolled for the study and compared with age and sex-matched 
30 normal healthy controls. Fasting blood samples were obtained from 
each participant.
Exclusion criteria
1. Patients having personal or family history of thyroid disease and 
medication.
2. Patients having a history of cardiovascular disease, hypertension, 
diabetes, renal disorder, and liver disease.
3. Pregnant women or having past 2-year history of pregnancy and 
women with menopause.
4. A person using social habits, for example, tobacco, smoking, and 
alcoholics.
5. Patients suffering from any inflammatory disease, for example, 
periodontitis and rheumatoid arthritis.
Inclusion criteria
Recently diagnosed SCH patients were included and normal healthy 
adults were included in the study. The age group criterion for this study 
was from 20 to 45 years.
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org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i9.26807
Research Article
357
Asian J Pharm Clin Res, Vol 11, Issue 9, 2018, 356-359
 Kumar et al. 
Methods
Baseline parameters including age and body mass index (BMI) were 
noted. BMI was calculated, dividing weight in a kilogram of an individual 
with the square of the height of that individual in the meter [9]. Blood 
parameters (TSH, FT4, T3, total cholesterol [TC], triglycerides [TGs], 
high-density lipoprotein [HDL] cholesterol, LDL-cholesterol, very low-
density lipoprotein [VLDL], lipoprotein ratios, and Hs-CRP) were also 
measured. SCH patients were having elevated concentration of TSH 
(>6.0 μIU/ml) along with normal concentrations of thyroid hormones. 
Thyroid profile including TSH, FT4, and T3 wasss measured by an 
enzyme-linked immunosorbent assay (ELISA) [10]. TC, TG, and HDL-
cholesterol were measured by CHOD-POD method, GPO-PAP method, 
and CHOD-POD/phosphotungstic method [11]. LDL-cholesterol and 
VLDL were measured by Friedewald formula [12]. Lipoprotein ratios 
including TC/HDL-cholesterol and LDL-cholesterol/HDL-cholesterol 
were also calculated [11]. Hs-CRP was also measured by ELISA 
method [13].
Statistical analysis
All the variables were expressed in mean±SD. An unpaired student’s 
t-test was applied to the groups to differentiate various parameters. 
A linear regression analysis was used for association between TSH 
and Hs-CRP in SCH patients. A p<0.05 was considered statistically 
significant. The statistical software Statistical package for the Social 
Science version 20.0 was used for statistical analysis.
RESULTS
In this study, significant results were obtained. BMI was higher in SCH 
group compared to control group. The result was highly significant 
(<0.01). In thyroid profile, TSH was significantly (<0.01) different 
between the groups (Table 1). In lipid profile, elevated concentration 
of the TC, TG, LDL cholesterol, and VLDL was higher in SCH patients. 
These higher concentrations were significantly (<0.05) different when 
compared with control group. HDL cholesterol was significantly (<0.01) 
higher in the control group compared to SCH group. Lipoprotein ratios 
including TC/HDL-cholesterol and LDL-cholesterol/HDL-cholesterol 
were significantly (<0.01) higher in SCH group. Serum concentration 
of Hs-CRP was significantly (<0.01) different between the groups 
(Fig. 1). The level of Hs-CRP was higher in SCH group (Table 2). There 
was a significant positive association between TSH and Hs-CRP in SCH 
patients (Table 3).
DISCUSSION
SCH patients are generally asymptomatic or present with few to 
various symptoms of overt hypothyroidism [14]. Patients with SCH 
in this study are characterized by the presence of dyslipidemia, 
which is the basic reason for developing cardiovascular disease [15]. 
Weight gain is quite common in hypothyroidism [16], and it is 
also observed in SCH patients since they are characterized with 
increased BMI when compared to normal healthy adults. Gupta et al. 
supported this finding by suggesting a positive association between 
TSH and BMI during a study on SCH women [17]. There was an 
elevated concentration of TC and LDL cholesterol in SCH patients. 
In support of this, Hueston and Pearson reported the presence of 
hypercholesterolemia in patients with SCH [18]. In comparison 
to this, mean concentration of HDL-cholesterol was lower in SCH 
group compared to control group. Erdem et al. also supported 
this result when observed a negative association between HDL-
cholesterol and TSH [19]. TG an important component of metabolic 
syndrome also found to be higher in patients with SCH compared 
to control group [20]. In addition to this, Marwaha et al. reported 
that dyslipidemia is present in SCH patients having TSH >10 mIU/L, 
not in patients with TSH <10 mIU/L [21]. However, in this study, 
elevated concentrations of lipid parameters were observed which 
is supported by Regmi et al. when they suggested that the risk of 
cardiovascular disease may not be avoided in SCH patients having 
TSH <10 mIU/L and these patients should be treated with caution 
due to the presence of dyslipidemia [22]. It was also stated that 
although the developing risk of cardiovascular disease was greater 
in SCH patients having TSH >10 μIU/ml, consideration should also be 
given to the patients having TSH <10 μIU/ml [23]. Lipoprotein ratios 
including TC/HDL-cholesterol and LDL cholesterol/HDL cholesterol 
are the better predictor of cardiovascular risk and atherosclerosis 
Table 1: Baseline parameters between SCH and control group
S. No. Parameters SCH group Control group p value
1. Age 34.50±3.25 35.0±3.35 >0.05
2. BMI 26.44±2.19 21.98±1.40 <0.01
3. TSH 8.47±1.20 1.81±0.41 <0.01
4. FT4 1.20±0.29 1.19±0.25 >0.05
5. T3 0.94±0.12 1.06±0.30 <0.05
Variables were expressed in Mean±SD. A p<0.05 was statistically significant. 
SCH: Subclinical hypothyroidism, TSH: Thyroid-stimulating hormone, BMI: 
Body mass index
Table 2: Lipid profile and Hs‑CRP between the groups
S. No. Parameters SCH group Control group p value
1. TC 197.04±19.81 185.73±9.52 <0.01
2. TG 117.93±23.95 105.00±22.27 <0.05
3. HDL-C 43.16±3.17 47.46±4.15 <0.01
4. LDL-C 128.68±19.91 117.48±10.04 <0.01
5. VLDL 23.66±4.80 20.97±4.49 <0.05
6. TC/HDL-C 4.57±0.50 3.95±0.40 <0.01
7. LDL-C/HDL-C 2.99±0.51 2.49±0.35 <0.01
8. Hs-CRP 3.03±0.37 1.63±0.38 <0.01
Variables were expressed in Mean±SD. A p<0.05 was statistically significant. 
Hs-CRP: High-sensitive C-reactive protein, LDL-C: Low-density lipoprotein 
cholesterol, HDL-C: High-density lipoprotein cholesterol, VLDL: Very 
Low-density lipoprotein cholesterol, TC: Total cholesterol, TGs: Triglycerides, 
SCH: Subclinical hypothyroidism
Fig. 1: Bar diagram representing the concentration of mean 
high‑sensitive C‑reactive protein with standard error between 
subclinical hypothyroidism and control group
Table 3: An association between TSH and Hs‑CRP in SCH group
Group Standardized β CI 95% p value
Lower Upper
SCH 0.363 0.002 0.536 <0.05
By linear regression analysis, a P value<0.05 was statistically significant. SCH: 
Subclinical hypothyroidism, Hs-CRP: High-sensitive C-reactive protein, TSH: 
Thyroid-stimulating hormone, CI: Confidence Interval
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than any other single lipid parameter [24]. There was an increased 
concentration of TC/HDL-cholesterol ratio and LDL cholesterol/
HDL-cholesterol ratio in patients with SCH compared to control 
group. Increased LDL-cholesterol/HDL-cholesterol ratio along with 
elevated TGs may predict the risk of ischemic heart disease [25]. 
Kvetny et al. also found that hypertriglyceridemia was associated 
with SCH males <50 years and indicated the sign of low-grade 
inflammation by an elevated concentration of Hs-CRP [26]. SCH 
patients may promote low-grade inflammation and develop the 
cardiovascular risk in future. CRP may account for additional factor 
for atherosclerosis in SCH patients [27]. Elevated concentration of 
Hs-CRP in this study also supported this finding. Gupta et al. reported 
the findings on SCH male patients with increased concentration CRP 
and other inflammatory markers and stated that SCH patients are 
characterized by cardiovascular abnormalities [28]. The presence of 
dyslipidemia in SCH patients including the elevated concentration 
of TC, increased TG, lower HDL-cholesterol, and abnormal LDL-
cholesterol along with the increased concentration of Hs-CRP can 
lead to the development of atherosclerosis [29]. Tuzcu et al. also 
reported similar findings in terms of LDL-cholesterol and Hs-CRP 
in SCH patients and suggested that low-grade inflammation may be 
promoted by an elevated concentration of Hs-CRP [30]. A study from 
a Taiwanese population also found a positive association between 
SCH and elevated quartiles of Hs-CRP [31]. Increased concentration 
of Hs-CRP and elevated lipoprotein ratios may predict the risk of 
cardiovascular disease in SCH patients [32].
CONCLUSION
The outcomes of this cross-sectional study revealed that there is an 
increased concentration of lipid parameters in patients with mild 
hypothyroidism having TSH <10 μIU/ml. Elevated lipoprotein ratios 
may suggest the developing risk of atherosclerosis in SCH patients. 
Higher concentration of Hs-CRP suggests the presence of low-grade 
inflammation, which may be the sign of developing cardiovascular 
abnormalities in patients with SCH. On concluding, patients with SCH 
having TSH <10 μIU/ml should be treated with caution and monitored 
carefully.
Limitations
Since it was an short-term studentship (STS) project for a limited time 
period, the only limitation of this study was its sample size. Hence, the 
more studies should be conducted with large sample size along with 
others establish marker to confirm this association.
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